Refuav0.4.1

A pharmaceutical company uses Refua to computationally fold and score protein-ligand complexes for a new target, estimating binding affinities to prioritize which small molecules to synthesize and test in vitro, reducing wet-lab costs and accelerating lead identification.

A biotech startup employs Refua to model and score protein-protein complexes, identifying potential inhibitors for disease-related interactions, followed by optional ADMET profiling to filter out compounds with poor pharmacokinetic properties early in the pipeline.

A university research group utilizes Refua's fold-only capability for DNA/RNA complexes to study structural dynamics and binding mechanisms, supporting grant proposals and publications without requiring experimental crystallography.

A CRO integrates Refua into its workflow to offer clients computational folding and affinity evaluation services for various biomolecular complexes, enhancing service offerings and attracting partnerships with drug discovery firms.

A drug discovery team uses Refua's optional ADMET tool to predict absorption, distribution, metabolism, excretion, and toxicity for SMILES ligands, refining lead compounds before synthesis to improve clinical trial success rates.

Offer Refua as a cloud-based platform where users pay subscription fees to access computational folding, scoring, and ADMET tools via the MCP server, targeting small to mid-sized biotech companies without in-house GPU infrastructure.

Provide consulting services to help pharmaceutical and biotech firms integrate Refua into their existing drug discovery pipelines, including custom tool development and workflow optimization, charging project-based or hourly rates.

License Refua to universities and research institutes at reduced costs for non-commercial use, fostering adoption in academic settings and generating revenue through tiered licensing fees for commercial spin-offs.